Outcome of a single XEN microstent implant for glaucoma patients with different types of glaucoma

BMC Ophthalmology

Table 3 Clinical success rates for different groups of glaucoma

	Complete success (A)	Qualified success (A)	Complete success (B)	Qualified success (B)	Complete success (C)	Qualified success (C)
complete group	60%	74%	51%	61%	45%	56%
POAG	54%	71%	45%	57%	29%	38%
NTG	60%	60%	60%	60%	20%	20%
PEX	86%	91%	77%	82%	50%	59%
secondary glaucoma	75%	75%	58%	58%	50%	50%
Kruskal-Wallis test	*p =* 0.03	p = 0.22	p = 0.07	p = 0.17	p = 0.17	*p =* 0.01

Clinical Success defined as complete (without the use of IOP-lowering drugs) and qualified (with the use of additional IOP-lowering drugs) success for the complete treated group of eyes and the four subgroups of the different glaucoma types (A) IOP reduction of ≥20% from baseline and resulting IOP of < 21 mmHg; complete success (B) IOP reduction of ≥30% from baseline and resulting IOP of < 18 mmHg; complete success (C) IOP reduction of ≥40% from baseline and resulting IOP of < 15 mmHg). Additionally, distribution of achieved success levels was compared between treatment groups using Kruskal-Wallis test

ISSN: 1471-2415